These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37138965)

  • 1. XPERT
    Borges PCC; Spencer HB; Barbosa C; Costa V; Furtado A; Leal MC; Lopes C; Ferreira D; Carvalho AL; Dos-Santos-Silva I; Santos LL
    Ecancermedicalscience; 2023; 17():1530. PubMed ID: 37138965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing Country.
    Mugabe M; Ho KE; Ruhangaza D; Milner D; Rugwizangoga B; Chu VC; Wu NC; Rizo A; Weidler JM; Wong W; Bates M; Brock JE
    Am J Clin Pathol; 2021 Oct; 156(5):766-776. PubMed ID: 34050358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
    Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
    Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
    ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the Xpert Breast Cancer STRAT 4 Assay on the GeneXpert instrument to Assess Hormone Receptor, Ki67, and HER2 Gene Expression Status in Breast Cancer Tissue Samples.
    Sewanywa L; Hale M; Michelow P; Mayne E; Wiggill T
    Appl Immunohistochem Mol Morphol; 2023 Oct; 31(9):613-620. PubMed ID: 37800656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
    Janeva S; Parris TZ; Nasic S; De Lara S; Larsson K; Audisio RA; Olofsson Bagge R; Kovács A
    BMC Cancer; 2021 Apr; 21(1):439. PubMed ID: 33879115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproducibility of mRNA-Based Testing of
    Erber R; Hartmann A; Fasching PA; Ruebner M; Stöhr R; Beckmann MW; Zentgraf M; Popp V; Weidler J; Simon I; Becker S; Huebner H; Fischer J; Guerini Rocco E; Viale G; Cayre A; Penault-Llorca F; Caniego Casas T; Pérez-Miés B; Palacios J; Jank P; Denkert C; Khoury L; Mairinger T; Ferrazzi F
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.
    Gupta S; Mani NR; Carvajal-Hausdorf DE; Bossuyt V; Ho K; Weidler J; Wong W; Rhees B; Bates M; Rimm DL
    Lab Invest; 2018 Aug; 98(8):1076-1083. PubMed ID: 29858579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of
    Carretero-Barrio I; Caniego-Casas T; Rosas M; Sánchez MC; Martínez-Jáñez N; Chiva M; Sarrió D; Moreno-Bueno G; Palacios J; Pérez-Mies B
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry versus PCR Technology for Molecular Subtyping of Breast Cancer: Multicentered Expereinces from Addis Ababa, Ethiopia.
    Oma D; Teklemariam M; Seifu D; Desalegn Z; Anberbir E; Abebe T; Mequannent S; Tebeje S; Labisso WL
    J Cancer Prev; 2023 Jun; 28(2):64-74. PubMed ID: 37434799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
    Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
    Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
    BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer molecular diagnostics in Rwanda: a cost-minimization study of immunohistochemistry versus a novel GeneXpert
    Erfani P; Gaga E; Hakizimana E; Kayitare E; Mugunga JC; Shyirambere C; Milner DA; Shulman LN; Ruhangaza D; Fadelu T
    Bull World Health Organ; 2023 Jan; 101(1):10-19. PubMed ID: 36593782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
    Park MM; Ebel JJ; Zhao W; Zynger DL
    Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
    Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
    Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of EDTA decalcification on estrogen receptor and progesterone receptor immunohistochemistry and HER2/neu fluorescence in situ hybridization in breast carcinoma.
    Washburn E; Tang X; Caruso C; Walls M; Han B
    Hum Pathol; 2021 Nov; 117():108-114. PubMed ID: 34461131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
    Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
    Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.